Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
Denali Therapeutics (DNLI) Stock Price & Analysis
430 Followers
DNLI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.45 - $33.31
Previous Close$18.52
Volume39.94K
Average Volume (3M)890.93K
Market Cap
$2.48B
Enterprise Value$1.42B
Total Cash (Recent Filing)$1.19B
Total Debt (Recent Filing)$55.52M
Price to Earnings (P/E)-19.1
Beta1.49
Next Earnings
Feb 26, 2024EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding138,196,848
10 Day Avg. Volume800,116
30 Day Avg. Volume890,927
Standard Deviation0.17
R-Squared0.14
Alpha0.00819
Financial Highlights & Ratios
Price to Book (P/B)2.14
Price to Sales (P/S)23.60
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.28
Enterprise Value/Gross Profit13.13
Enterprise Value/Ebitda4.87
Forecast
1Y Price Target
$50.57Price Target Upside182.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Denali Therapeutics News
Ownership Overview
0.00% Insiders
24.34% Mutual Funds
49.92% Other Institutional Investors
25.75% Public Companies and
Individual Investors
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $15.45 and its highest was $33.31 in the past 12 months.
What is Denali Therapeutics’s market cap?
Currently, no data Available
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Feb 26, 2024 which is in 87 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Nov 08, 2023. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.81 by $0.09.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -$0.8.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 138,196,850 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.81. Following the earnings report the stock price went down -4.946%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Among the largest hedge funds holding Denali Therapeutics’s share is Flagship Pioneering Inc.. It holds Denali Therapeutics’s shares valued at 54M.
---
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.57 (182.36% Upside)
$50.57 (182.36% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.4%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Positive
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.96%
12-Months-Change
Fundamentals
Return on Equity
-12.90%
Trailing 12-Months
Asset Growth
0.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Denali Therapeutics
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
---
Top 5 ETFs holding DNLI
Vanguard Total Stock Market ETF
$61.13M
Vanguard Health Care ETF
$7.04M
Vanguard Russell 3000 ETF
$145.09K
Strive 1000 Growth ETF
$1.82K
V-Shares US Leadership Diversity ETF
$73.56
Up to five ETFs with an Outperform Smart Score that hold DNLI. The ETFs are listed according to market value of DNLI within the ETF
Ultragenyx Pharmaceutical
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
---